Christopher Dvorak, MD

Prof of Clinical Pediatrics
M_PEDS-BONE MARROW TRANSPLANT
Custom People Group

Chris Dvorak is a pediatric hematopoietic cell transplanter with a research focus dedicated to improving the safety, accessibility, and curative potential of hematopoietic cell transplantation (HCT) in children and adolescents. His research goals have evolved from reducing transplantation-related complications to fundamentally optimizing transplantation through donor selection, graft engineering, and individualized conditioning. Specific areas of focus include:
A. Severe combined immunodeficiency and immune reconstitution
Addressing fundamental questions in transplantation for severe combined immunodeficiency (SCID), particularly the balance between donor engraftment, immune recovery, and the toxicities of conditioning.
B. Transplantation for rare pediatric malignancies
His research has addressed difficult-to-treat pediatric hematological malignancies, including juvenile myelomonocytic leukemia (JMML) and acute promyelocytic leukemia (APL). These studies reflect a commitment to developing evidence for uncommon diseases, where single-center experience is often insufficient and collaborative research is especially important.
C. Supportive care, infections, and transplant-related mortality
His clinical research program is focused not simply on achieving engraftment, but on improving the entire transplantation experience. His leadership in cooperative supportive-care research provides a mechanism for translating clinical questions into multicenter trials.
D. Precision conditioning and pharmacokinetic-guided transplantation
Along with his research partner, Janel Long-Boyle, PharmD, PhD, his research focuses on the replacement of conventional body-size or weight-based drug dosing with individualized exposure-based strategies aimed at improving the therapeutic index of conditioning.
E. Haploidentical transplantation, donor selection, and graft engineering
His more recent scholarship has increasingly focused on optimizing alternative-donor transplantation, particularly through TCRαβ T-cell depletion and improved donor selection.